Alumis Corp - ALMS EV/EBITDA Multiple

Corporate emblem and logo of Alumis Corp (ALMS)

Alumis Inc. (ALMS) automates the discovery of treatments for autoimmune diseases through robotics and AI, eliminating routine tasks for scientists. The company is developing unique targeted therapies and plans to implement premium pricing leveraged by its patents. Currently, the business is focused on the final stages of trials for TYK2 inhibitors to treat neuropathologies. This historical price chart confirms these achievements, while the EV/EBITDA metric stands at 0.00.

ALMS (Alumis Corp) EV/EBITDA Multiple history from 11/23/2025 to 11/10/2026

ALMS (alumis.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Alumis Corp|ALMS - Broker Consensus Forecast
- issuer market value details:
Market Capitalization Alumis Pharma|ALMS - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Alumis|ALMS - Book Capitalization|Market Value to Book Value Ratio alumis.com|ALMS - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Alumis Inc.|ALMS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Alumis|ALMS - Company Debts|Debt to Book Capitalization Ratio Alumis Pharma|ALMS - Long-Term Debt|Company Short-Term Debts Alumis|Quick Liquidity Indicator alumis.com
- net income and valuation multiples indicators:
ALMS - Company Net Income|Projected Future Earnings Alumis Inc.|ALMS - P/E Multiple|Future Price to Earnings Alumis Inc.|ALMS - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Alumis Pharma|ALMS - Operating profit EBITDA|Earnings per share for the last twelve months Alumis|ALMS - Net earnings per share for the last 12 months|Quarterly EPS earnings growth alumis.com|ALMS - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Alumis Inc.
Summary company analytics:ALMS (Alumis Corp)
Original product of Alumis

For Alumis Inc., which is developing costly treatment programs for autoimmune pathologies, this indicator assesses the business value relative to operating profit before depreciation and interest. The metric reveals hidden debt leverage, which is often masked by speculative growth in share prices. By analyzing the EV/EBITDA ratio dynamics of this capital-intensive business, an investor can uncover a critical gap between the market price and actual cash flow. This allows for an assessment of the company's resilience to the risks of clinical failures and competition.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jazz Pharma JAZZ|CYTK: Enterprise Value to Operating Income Before Depreciation|PTC Therapeutics, Inc. - EV/EBITDA Multiple|Company Value to EBITDA scholarrock.com|CNTA (Centessa) - Enterprise Value to EBITDA Ratio|Dyne Therapeutics Inc (DYN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Edgewise Pharma|RAPP: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Zevra Therapeutics (ZVRA)|CTNM - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Larimar Therapeutics, Inc. LRMR|Capricor Therapeutics Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRDA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Channel Pharma|MNOV: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple serinatherapeutics.com SER|Enterprise Value to EBITDA Ratio BTAI|Company Value to EBITDA ProMIS PMN|EV/EBITDA Multiple APUS|EV/EBITDA Multiple aeonbiopharma.com (AEON)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NLS Pharmaceutics NLSP|Bionomics Ltd. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|HUGE: Enterprise Value to EBITDA Ratio|RETA - EV/EBITDA Multiple